← Browse by Condition
Medical Condition

itp immune thrombocytopenia

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 2, Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for itp immune thrombocytopenia sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — itp immune thrombocytopenia Clinical Trials

How many clinical trials are currently recruiting for itp immune thrombocytopenia?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for itp immune thrombocytopenia, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for itp immune thrombocytopenia?
itp immune thrombocytopenia research spans Phase 1 (1 trial), Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a itp immune thrombocytopenia clinical trial?
Eligibility criteria for itp immune thrombocytopenia trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
2
Phase 3
1
Top Sponsors
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China 1 trial
argenx 1 trial

Recruiting Clinical Trials

NCT06352281 Phase 1, Phase 2
Recruiting
Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)
Enrollment
10 pts
Location
China
Sponsor
920th Hospital of Joint Logist...
View Trial →
NCT07194850 Phase 2, Phase 3
Recruiting
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
Enrollment
24 pts
Location
Germany, Italy, Pola...
Sponsor
argenx
View Trial →

Related Conditions

immune thrombocytopenia itp (1) itp (1) immune thrombocytopenic purpura (1) immune thrombocytopenic purpura itp (1) idiopathic thrombocytopenic purpura (1) idiopathic thrombocytopenic purpura itp (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology